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Abstract
VILIP-1, a member of the neuronal Ca
2+ sensor protein family, is able to act as a tumor suppressor in carcinoma cells by
inhibiting cell proliferation and migration. In order to study the role of VILIP-1 in skin carcinogenesis we generated
transgenic mice overexpressing VILIP-1 in epidermis under the control of the bovine keratin K5 promoter (K5-VILIP-1). We
studied the susceptibility of FVB wild type and VILIP-1 transgenic mice to chemically mediated carcinogenesis. After 30
weeks of treatment with a two-stage carcinogenesis protocol, all animals showed numerous skin tumors. Nevertheless, K5-
VILIP-1 mice showed decreased squamous cell carcinoma (SCC) multiplicity of ,49% (p,0.02) with respect to the
corresponding SCC multiplicity observed in wild type (WT) mice. In addition, the relative percentage of low-grade cutaneous
SCCs grade I (defined by the differentiation pattern according to the Broders grading scale) increased approximately 50% in
the K5-VILIP1 mice when compared with SCCs in WT mice. Similar tendency was observed using a complete carcinogenesis
protocol for skin carcinogenesis using benzo(a)pyrene (B(a)P). Further studies of tumors and primary epidermal keratinocyte
cultures showed that matrix metalloproteinase 9 (MMP-9) levels and cell proliferation decreased in K5-VILIP-1 mice when
compared with their wild counterparts. In addition tissue inhibitor of metalloproteinase 1 (TIMP-1) expression was higher in
K5-VILIP-1 keratinocytes. These results show that VILIP-1 overexpression decreases the susceptibility to skin carcinogenesis
in experimental mouse cancer models, thus supporting its role as a tumor suppressor gene.
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Introduction
The chemical carcinogenesis model of skin cancer has been used
extensively to better understand the sequence of events and the
nature of lesions that appear during the course of the carcinogenesis
process [1]. These studies resulted in innumerable findings and
advances in the knowledge of tumor development, and furthered
the concept that very small doses of carcinogen followed by
hyperplasiogenic stimuli can result in cancer. Furthermore these
findings collected during various decades, have been enhanced by
more recent molecular data that established that many of the stages
of carcinogenesis are due to a large extent to specific changes in
oncogenes and tumor suppressor genes [2].
I nap r e v i o u ss t u d y ,u s i n gap a i r of low grade/high grade mouse
SCC cell lines derived from the same primary tumor (CC4B/CC4A
cells), we identified by differential display a gene product that was lost
in invasive tumor cells [3]. This protein, VILIP-1 (gene name VSNL1),
was established to be a member of the visinin-recoverin or neuronal
calcium sensor (NCS) protein family [4,5] and has been identified as
having a role in human neurological disease and cancer [6]. The
VILIP protein familycontains 4 EF-handcalcium-binding motifs,and
a consensus myristoylation site at its N-terminus. VILIP-1 modulates
the levels of cyclic nucleotides by indirect or direct interactions with
adenylyl and guanylyl cyclases [7,8]. The modulation of cyclic
adenosine monophosphate (cAMP) by VILIP-1 has been previously
studied in nerve cells and has been demonstrated to be the mediator of
the effect of VILIP-1 on cell proliferation, differentiation, and
migration [5,7,8].We reported that VILIP-1 is differentiallyexpressed
in murine skin tumors and cell lines of different degrees of
aggressiveness and that transfection of two high grade mouse SCC
lines with the VILIP-1 cDNA, increased cAMP levels, leading to
diminished MMP-9 activity together with a significant reduction in
the invasive properties of the carcinoma cells [9].
In order to study the role of VILIP-1 during in vivo carci-
nogenesis we developed transgenic mice that express VILIP-1 in
the epidermal basal layer. Although transgenic mice did not seem
to have gross abnormalities, a more in depth analysis revealed that
the tumor suppressive ability of this gene resulted in a decreased
susceptibility to skin carcinogenesis.
Results
Generation and characterization of K5-VILIP-1 transgenic
mice
To study the effects of VILIP-1 expression on the highly
proliferative epidermal basal cells, the full-length human VILIP-1
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VILIP-1 to the basal epidermal keratinocytes. The construct
(Figure 1A) contains the bovine K5 promoter, followed by the first
intron from rabbit b-globin to enhance the efficiency of
transcription, the full-length VILIP-1 cDNA and, finally the
polyadenylation signal from SV-40. Two founders were produced
and the one with the highest number of transgene copies was
selected to generate a transgenic line (data not shown). The
selected founder and its progeny were genotyped by PCR of
genomic DNA using the primers amplifying a DNA segment of
about 360 bp. A representative genotyping experiment is shown in
Figure 1B.
Transgene copy number was assessed by Southern blot analysis.
The transgenic line used for these experiments contained higher-
than-18 copies of the transgene (Figure 1C). Transgene expression
was confirmed by Western blot analysis of VILIP-1 protein
expression. As source of proteins we used lysates from primary
keratinocyte cultures obtained from newborn mice. VILIP-1
protein was readily detected in the keratinocytes from transgenic
mice but not from wild-type counterparts (Figure 1D). Since
VILIP-1 affects the levels of intracellular cAMP [3], the
concentration of this cyclic nucleotide was measured in the
primary epidermal keratinocytes derived from WT and K5-
VILIP-1mice. Keratinocytes derived from the transgenic mice
Figure 1. Generation of VILIP-1 transgenic mice. (A) K5-VILIP-1 construct. The two arrows above the b-globin intron box indicate the position of
the specific primers used in PCR genotyping. (B) PCR from DNA extracted from WT and K5-VILIP-1 transgenic mouse tails, amplified with b-globin
primers are shown. Lanes 1 to 3 correspond to three different K5-VILIP-1 transgenic mice showing positive band, lanes 4 to 6 correspond to three
different non-transgenic mice, negative for the transgene band (300–400 bp). (C) Determination of the number of copies of the transgene by
Southern blot analysis from 2 animals from the selected transgenic mouse line compared to copy standards as described in Material and Methods. (D)
Western blot showing differential expression of VILIP-1 protein in primary keratinocyte cultures derived from WT (lanes 1 to 2) and transgenic mouse
epidermis (lanes 3 to 4). (E) Intracellular concentrations of cAMP in primary epidermal keratinocytes derived from K5-VILIP transgenic mice (VP+) was
higher than that from WT mice (VP-) (p=1.2E-05). (F) Gelatinase zymography showing decreased MMP-9 activity of K5-VILIP-1 supernatant (+) derived
from primary keratinocyte cultures when compared with their WT counterpart (2). Molecular weights corresponding to standards are shown at the
left. (G) Relative TIMP-1 concentration in supernatant derived from K5-VILIP-1 transgenic (VP+) epidermal keratinocyte cultures was higher than that
from WT (VP-) (p=3.6E-09). The values have been normalized with respect to the WT.
doi:10.1371/journal.pone.0010196.g001
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counterparts (Figure 1E). Previous evaluation of VILIP-1 in
transfected cells demonstrated decreased levels of MMP-9 [3].
Thus, we decided to evaluate this metalloprotease in primary
keratinocytes. As depicted in Figure 1F, primary keratinocytes
from K5-VILIP-1 transgenic mice showed lower levels of MMP-9
activity than keratinocytes derived from WT mice. Furthermore,
we were able to demonstrate that at least part of this MMP-9
activity reduction in the transgenic-derived cells was due to an
elevation of TIMP-1 expression in these cells when compared to
WT keratinocytes (Figure 1G).
Overexpression of VILIP-1 induces epidermal proliferative
changes
The gross and histological examination of the untreated skin of
animals up to six months of age showed no deviations from normal.
Nevertheless, immunohistochemistry (IHC) analysis of skin and
other squamous epithelia showed that VILIP-1 was markedly
overexpressed in these tissues. The overexpression was very obvious
in the transgenic mice (compare Figures 2A and 2B) and could also
be used to distinguish between transgenic and WT mice using small
fragments of tail skin that were also used for PCR confirmation of
the transgenic status. Minimal or absent VILIP-1 immunostain was
Figure 2. IHC analysis of VILIP-1 expression in mouse tissues. Normal tail skin of WT (A), and K5-VILIP-1 transgenic mouse (B). Note that a few
basal keratinocytes (arrow), especially in the supra-sebaceous or infundibular portion of the hair follicle express VILIP-1 in the normal tail epidermis
(A). In the transgenic epidermis there is a massive overexpression of VILIP-1 in practically every layer of the epidermis and adnexa (B). Similar
overexpression is noted in the dorsal skin of K5-VILIP-1 transgenic mouse (C). Other VILIP-1-overexpressing epithelia in transgenic mice shown are:
esophagus (D), bronchial epithelium (arrow) (E) and biliary duct epithelium (F). VILIP-1 immunohistochemistry counterstained with hematoxylin,
X 200.
doi:10.1371/journal.pone.0010196.g002
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basal keratinocytes showed mild immunostain in a focal pattern.
Conversely, K5-VILIP-1 epidermis exhibited intense and diffuse
immunostain in the basal and spinous layers (Figure 2B, C).
SimilarlyVILIP-1,thatwasnotseenoronlymarginallyexpressedin
other epithelia from WT mice, e.g., oral epithelia, bronchial
mucosa,and biliaryduct epithelium,was markedlyoverexpressed in
K5-VILIP-1 animals (Figures 2D, E, F).
The effect of VILIP-1 overexpression on epidermal thickness
and basal keratinocytes proliferation was evaluated in hematoxylin
and eosin (H&E) stained specimens and using BrdU immunohis-
tochemistry respectively. A statistically significant difference was
seen between the baseline epidermal thickness of WT and K5-
VILIP-1 mouse epidermis in untreated mice. The measurements
of the dorsal epidermal thickness in WT and transgenic mice
indicated that epidermal thickness was slightly decreased by the
expression of the transgene (p,0.02) (Figure 3A, left panel).
Similarly, the labeling index of bromodeoxyuridine (BrdU) in basal
keratinocytes (expressed as labeled basal cells per mm of basement
membrane) showed that K5-VILIP-1 epidermis had a lower
incorporation rate than the WT epidermis (42% decrease,
p,0.005) (Figure 3B, left panel). Furthermore, decreased suscep-
tibility to the hyperplasiogenic and proliferative effects of 12-0-
Tetradecanoylphorbol-13-acetate (TPA) was observed after acute
topical treatment. The epidermis from transgenic mice showed an
approximately 22% decrease in thickness compared to their WT
counterparts after one week of TPA treatment (Figure 3A, right
panel). Proliferation was also evaluated by BrdU incorporation
after TPA treatment. BrdU incorporation into K5-VILIP-1
epidermis decreased approximately 50%, with respect to the
WT levels (Figure 3B, right panel; this can be visualized by
comparing the micrographs in panels 3E and 3F).
Overexpression of VILIP-1 decreases susceptibility to skin
cancer
In order to determine the effects of VILIP-1 overexpression on
SCC development, two different chemical carcinogenesis protocols
were applied to the mouse skin. The two stage carcinogenesis
protocol showed that K5-VILIP-1 mice had a 49% decrease in the
SCC tumor multiplicity when compared to WT mice at week 30
(p,0.02) (Figure 4A). Interestingly, the ratio of SCC/papilloma
was reduced more than two-fold in transgenic animals when
compared to WT mice (Figure 4B) (p,0.01). This translates into a
conversion rate of papillomas to carcinomas in this experiment of
23 for K5-VILIP-1 mice and 9 for WT mice. The transgenic mice
showed a predominance of well differentiated SCC of grade I,
74% to 49% in WT mice (Figures 4C and 4D). Although not
statistically significant, the tumor multiplicity of SCC I in K5-
VILIP-1 mice was lower than in WT mice (0.68 SSCI/mouse
versus 0.88 SCCI/mouse). When considering tumor multiplicity of
higher grade tumors SCC II, III and IV there was a statistically
significant difference, i.e. 0.08 SCCs/mouse in K5-VILIP-1 mice
versus 0.31 in WT mice (p,0.003). Also of interest was the
extremely low prevalence of high grade tumors in the K5-VILIP-1
mice, i.e., whereas in WT mice 13% of SCCs were of high grade
(grades III and IV), in K5-VILIP-1 transgenic mice this proportion
was only 4% (Figures 4C and 4D).
Figure 3. Effects of acute topical treatment with TPA. Mean epidermal thickness expressed in micrometers (A) shows a minor reduction of
epidermal thickness in K5-VILIP-1 dorsal interfollicular epidermis with respect to WT epidermis (acetone treated controls) (p,0.02). After 7 days of
TPA treatment (2 topical applications, at day 1 and day 4) there is an increase in epidermal thickness in both WT and transgenic mice. Note that this
increase is significantly lower in transgenic epidermis (p,0.001). Panel B shows a proliferation index calculated as the number of BrdU positively
stained basal keratinocytes per mm of basement membrane. Note significantly lower labeling index in control K5-VILIP-1 epidermis with respect to
WT epidermis (p,0.002). Similarly, after TPA treatment the transgenic epidermis showed significantly reduced cell proliferation (p,0.0005). Note a
general similarity in morphology between WT (C) and K5-VILIP-1 (D) dorsal epidermis stained with hematoxylin after acetone (control) treatment.
Nevertheless, one week after TPA treatment, both WT epidermis (E) and K5-VILIP-1 epidermis (F) are thicker that their respective controls.
Furthermore, WT epidermis treated with TPA (E) exhibits more BrdU-stained cells than the K5-VILIP-1 epidermis (F). BrdU immunohistochemistry
counterstained with hematoxylin, X200.
doi:10.1371/journal.pone.0010196.g003
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similar tendency. Although with this protocol, the SCC multiplic-
ity was higher than with the two stage carcinogenesis protocol, a
reduction of approximately 20% was noted at the end of the
experiment (between 35 to 40 weeks) in the K5-VILIP-1 with
respect to WT mice (Figure 5A) (p,0.05). Histopathological
analysis of the tumors at the final time point showed that there was
an even larger difference when microscopic tumors, that were not
detected grossly, were taken into account. This analysis showed
that the reduction of SCCs was even higher (33%) in K5-VILIP-1
mice with respect to WT mice (p,0.05). The predominance of
very well differentiated SCCs (Grade I) in transgenic mice, 63% up
from 49% in WT mice, was noteworthy. The average number of
high-grade tumors (II and III) per mouse was only 1 in K5-VILIP-
1 transgenic animals as compared to 1.8 in wild-type mice
(Figures 5B and 5C).
Differences in tumor characteristics
The proliferation rate of papillomas produced by the two stage
carcinogenesis protocol was determined by evaluating Ki67
expression of basal cells in WT and K5-VILIP mice at week 30.
Interestingly the labeling index (LI) with this proliferation marker
(percent of labeled cells stained in the basal layer) showed a
significant decrease in LI of papillomas derived from transgenic
mice with respect to similar benign tumors from WT mice (58% vs
76%, p=7.04E-06). When the same comparison was done
between SCCs from these two animal groups, a moderate but
non-significant KI67 LI decrease in transgenic-derived malignant
tumors was noted (52% vs 61%, p=0.069). In addition, we
noticed that the expression of MMP-9 was lower in transgenic-
derived SCCs than in the equivalent tumors from K5-VILIP-1
mice (Figures 6A–D), i.e., almost 5 times as many SCCs from WT
mice than SCCs from K5-VILIP-1 animals expressed high levels
(Positive 2) of MMP-9 (35% WT vs 8% K5-VILIP-1, p ,0.01).
Discussion
VILIP-1 is expressed in the central nervous system, where it
regulates cAMP levels, cell signaling and differentiation [5,7,8].
VILIP-1 is also widely expressed in sites outside the nervous system
such ashumanheart,lung,liverandtestisandmoderatelyexpressed
in ovary, kidney, spleen and pancreas, suggesting that VILIP-1
might be required for the maintenance of tissue homeostasis in
different organs [10]. Given the centralrole of VILIP-1 as a calcium
sensor in mediating cAMP response, deregulation of VILIP-1
expression may cause abnormalities in various non-nervous tissues.
In past reports, we have described that VILIP-1 expression is lost in
chemically-induced mouse SCC [3]. We have also shown that
VILIP-1 plays a critical role in regulating the invasive/metastatic
phenotype by decreasing cell proliferation and matrix degradation/
tumor cell invasiveness through a cAMP mediated pathway [3,9].
Furthermore, we have found that VILIP-1 is lost inaggressiveSCCs
of the human esophagus and lung suggesting a tumor suppressor
function [11,12].
In this report we demonstrate that the transgenic expression of
VILIP-1 targeted to the epidermis is able to decrease the baseline
levels of cell proliferation and that this downregulation of epidermal
proliferation is also very evident after short term treatment with the
hyperplasiogenic tumor promoter TPA. The decrease in epidermal
Figure 4. Responsiveness of WT and transgenic mice to two stage carcinogenesis protocol (DMBA/TPA). (A) Tumor multiplicity: SCC/
mouse. Note decreased number of carcinomas in transgenic compared to WT animals (p,0.02). (B) SCC/papilloma ratio indicating a sharp decrease in
K5-VILIP-1 with respect to WT mice (p,0.01). Histopathological grade is shown in Panels C and D: The relative distribution of SCCs according to their
histopathological grade is depicted in the pie charts. Note the predominance of SCC I tumors in K5-VILIP-1 mice.
doi:10.1371/journal.pone.0010196.g004
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of keratinocyte differentiation, especially K1 and loricrin (Figure
S1). The main effect on cell proliferation and differentiation is
attributable to the well known increase in cAMP levels in
keratinocytes overexpressing VILIP-1, described in detail in our
previous reports [3,9]. VILIP-1 expression also induced astrocytic
differentiation in C6 cells [13] and is associated with increased
squamous differentiation in human esophageal and lung tumors
[11,12]. In this context, it is noteworthy that Braunewell and
Gundelfinger were able to demonstrate that differentiation is
inducible using cAMP analogs [13]. Similar effects of cAMP have
been described in squamous cell lines and tissues in which cAMP
enhanced the expression of keratins such as K1 and K10 [14,15].
Perhaps the most significant effect of VILIP-1 overexpression in
epidermis is a decrease in MMP-9 activity. This was shown by us in
VILIP-1 transfected cells [3] and was considered a consequence of
increased cAMP activity [9]. In the present report we show that this
decrease in primary keratinocytes derived from K5-VILIP-1
transgenic mice is accompanied by a significant increase in
TIMP-1. This direct regulation of TIMP-1 levels by cAMP has
been demonstrated in several different cells and tissue types
[16,17,18,19] and may be the principal mechanism of TIMP-1
induction by VILIP-1 overexpression in the transgenic mouse skin.
In order to evaluate whether VILIP-1 could modulate
tumorigenesis and/or susceptibility to exogenous carcinogens we
applied well known carcinogenesis protocols that are widely
accepted as paradigms of epithelial carcinogenesis, i.e., the two
stage carcinogenesis and the complete carcinogensis protocols of
the mouse skin [20,21,22]. The decreased keratinocyte prolifer-
ation and increased squamous differentiation patterns observed in
transgenic epidermis have a direct correlation with our observa-
tions during skin carcinogenesis of K5-VILIP-1 mice that led to a
decreased sensitivity to skin carcinogenesis. In both carcinogenesis
protocols we observed a decrease of SCC multiplicity with respect
to WT mice that was close to 49% in the two stage carcinogenesis
experiment during the final weeks of the experiment (28-30 weeks)
and approximately 33% in the complete carcinogenesis experi-
ment at 36 to 40 weeks. In the two stage carcinogenesis
experiment it was noteworthy that the ratio of SCC to papillomas
was markedly decreased in K5-VILIP-1, indicating that the
conversion rate was diminished in transgenic mice. In addition to
this general decrease in the prevalence of SCC in K5-VILIP-1
mice, we observed a remarkable change in the distribution of
SCCs of different histopathological grades at the final time-point
of the experiments. In both carcinogenesis protocols the transgenic
mice had a predominance of low grade SCCs over high grade
Figure 5. Responsiveness of WT and transgenic mice to complete carcinogenesis using B(a)P. (A) Tumor multiplicity: SCC/mouse. Note
decreased number of carcinomas in transgenic compared to WT animals (p,0.05). Histopathological grade is shown in Panels B and C: The relative
distribution of SCCs according to their histopathological grade is depicted in the pie charts. Note the predominance of SCC I tumors in K5-VILIP-1
mice.
doi:10.1371/journal.pone.0010196.g005
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was clearly represented by the increase in SCC I, i.e., very well
differentiated SCCs, that constituted 74% of all SCCs in K5-
VILIP-1 mice versus only 49% of SCCs in WT mice treated with
the two stage carcinogenesis protocol. In the complete carcino-
genesis experiment, the difference was slightly lower, 69% in K5-
VILIP-1 mice versus 49% in WT mice. These changes in the
histopathological grades correlate well with our data on differen-
tiation patterns seen in the transgenic epidermis. VILIP-1
overexpression increases epidermal keratinocyte differentiation in
TPA treated skin and this tendency may influence the predom-
inance of well differentiated SCCs in transgenic mice. Decreased
cell proliferation could also be an important factor because quite
frequently well differentiated SCCs not only have more advanced
differentiation patterns than high grade SCCs but are also
characterized by a relatively slower cell proliferation [23,24,25].
This has also been seen in the tumors, especially in papillomas
from transgenic K5-VILIP-1 animals, which showed a significant
decrease in Ki67 labeling index with respect to the papillomas
from WT mice. A similar tendency was seen in SCCs.
Furthermore, MMP-9 expression in tumors from WT and
transgenic animals showed the same pattern of MMP-9 activity
seen in normal primary epidermal keratinocytes, i.e., tumors from
transgenic origin showed less MMP-9 expression than that seen in
tumors from WT mice treated with carcinogens.
Although, we evaluated local and distant metastases at the end
of the experiments we did not find statistically significant
differences (data not shown). This lack of differential metastatic
abilities between SCCs from transgenic and WT mice is probably
due to the fact that skin SCCs have relatively low and late
metastatic potential [26,27]. Furthermore, this inability to detect
metastases is enhanced by the present bioethical guidelines that
require culling animals that present with tumors larger than
10 mm diameter. The lack of significant metastases data
notwithstanding, tumor grading evaluation indicated that the
incidence of high grade SCCs, usually the most aggressive and
invasive tumors, were decreased in K5-VILIP-1 transgenic mice.
This data can be considered as evidence of decreased tumor
progression in mice overexpressing this protein. This is supported
by previous experiments demonstrating that overexpression of
VILIP-1 in murine SCCs cell lines decreased invasion and
migration [3].
In summary, transgenic VILIP-1 expression targeted to the
epidermis results in decreased proliferation patterns that render
the skin less susceptible to carcinogenesis. Furthermore, VILIP-1
overexpression attenuates the histotypes produced resulting in a
slower conversion to overt malignancy in the two stage
carcinogenesis protocol and a decreased prevalence of the most
advanced high grade SCCs in both carcinogenesis protocols.
These observations point to an inhibitory effect of VILIP-1
Figure 6. MMP-9 IHC analysis of the invasive front (arrow) of SCCs from a wild type mouse (A) and a K5-VILIP-1 (B) mouse treated
with a two stage carcinogenesis protocol. The asterisk shows the location of the skin muscle layer. MMP9 immunohistochemistry with
hematoxylin counterstain (X200). The pie charts show the percentage of SCCs exhibiting no immunostain (Negative), mild to moderate stain (Positive
1) and intense immunostain (Positive 2) in the WT (C) and transgenic (D) groups respectively.
doi:10.1371/journal.pone.0010196.g006
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progression.
Materials and Methods
Materials
12-0-Tetradecanoylphorbol-13-acetate (TPA), 7, 12-Dimethyl-
benz(a)anthracene (DMBA) and benzo(a)pyrene (B(a)P) were
purchased from Sigma–Aldrich (St Louis, MO). FVB/N mice,
6-8 weeks of age, were purchased from Taconic (Germantown,
NY) and were used as wild type controls.
Generation and identification of K5-VILIP-1 mice
A similar approach to the one used previously in our laboratory
to obtain transgenic mice was utilized [28]. The 0.85-kb full-length
human VILIP-1 cDNA (VSNL1) was excised from its parental
pCIneo vector using DraI, which produces a blunt-ended
fragment. The fragment was ligated into the SnaBI site between
the rabbit b-globin intron and polyadenylation sequences from a
vector described previously and inserted into the K5 expression
vector [29]. Orientation and integrity of the insert were confirmed
by restriction analysis and sequencing. The K5-VILIP-1 transgene
was microinjected into the pronuclei of mouse embryos obtained
from FVB female mice mated with FVB males. DNA was
extracted from clipped tails as described [30]. Mice were
genotyped by PCR analysis of tail DNA utilizing primers specific
for b-globin intron and the sequences of primers were: sense,
59TTCAGGGTGTTGTTTAGAAATGG; antisense, CAATAA-
GAATATTTCCACTCCA. All research involving animals was
conducted according to the relevant national and international
guidelines. All animals were kept in isolator cages in a pathogen-
specific free environment. All mice used in these experiments were
maintained on a 12:12 h light: dark cycle. Mice were given food
and water ad libitum throughout the experimental period. Tumor-
bearing mice were euthanized when the tumor was larger than
12 mm diameter, ulcerated or the animal had clear signs of
discomfort or disease (rapid weigh loss, weakness or listlessness).
The mice were cared for in accordance with the Guide for the
Care and Use of Laboratory Animals and the experimental
protocols were annually approved by the Institutional Animal
Care and Use Committee Fox Chase Cancer Center (protocol
No. 99-14). All animal experiments at our Institution must obtain
such an approval (our facility is ALALC approved).
Southern Blot analysis of copy number
10 mg of liver DNA was digested with EcoRI, and then
subjected to electrophoresis on 0.8% agarose and transferred to
Hybond N
+ (Amersham, Buckinghamshire, UK). The blot was
hybridized with a probe from transgene labeled by PrimerIt II
Random Primer Labeling kit (Stratagene, La Jolla, CA). The
transgene band to be detected is a 700-bp DNA fragment
generated by EcoRI digestion of chromosomal DNA. As a
standard for determining the copy number we digested the
pBSK5-VILIP-1 plasmid used for the microinjections with EcoRI,
separated by 1% agarose gels and the corresponding 700 bp band
was excised and purified. The amount of controls was calculated as
describe in http://www.med.umich.edu/tamc/spike.html. Esti-
mation of the copy number of the transgene was done by
densitometry, comparing the intensity of the signals generated by
hybridization of the
32P-dCTP-labeled probe with DNA extracted
from transgenic animals with those generated by controls
containing 0, 1, 3, 9 and 18 copies of the 700-bp band per
genome.
Culture of newborn keratinocytes and Western blot
analysis of VILIP-1 expression
Primary epidermal keratinocytes from newborn mice were used
to determine expression levels of VILIP-1 because of their
suitability for in vitro growth and further molecular analyses.
Primary epidermal keratinocytes were established in vitro as
described [31,32]. Briefly, 1–3 days-old mice were sacrificed; the
skin was washed in a 1:10 solution of Betadine, rinsed twice in
sterile water and twice in 70% alcohol. The skin was removed and
floated overnight on 2 ml of trypsin (0.25% without EDTA). The
epidermis was separated from the dermis, minced and resus-
pended in HiCa medium containing calcium-free MEM Eagle
(#06-174G, Lonza, Walkersville, MD), 8% chelexed serum
(provided by Cell Culture Facility, Fox Chase Cancer Center)
and 1.3 mM calcium. The resulting cell suspension was triturated
by pipetting up and down and applied to 100-mm cell strainer (BD
Biosciences, Bedford, MA). After centrifugation, the pellet was
resuspended in 0.2 mM calcium medium (calcium-free MEM
Eagle, 8% chelexed serum and 0.2 mM calcium) and counted.
The cells were initially plated in 0.2 mM calcium medium for 1
day, and then plated in KGM growth medium composed of 1 part
of KBM Basal Medium (#CC-3101), 2 parts of KBM Basal
Medium without calcium (#CC-3104) and bovine pituitary gland
extract (from #CC-4131). The keratinocytes grown in culture
dishes were lysed and subjected to VILIP-1 Western blot analysis
according to our previously reported protocol [12].
Mouse cAMP assay
Mouse primary keratinocytes were seeded onto 96-well culture
plate and allowed to grow till at least 70% confluency was reached.
The cells were lysed and the intracellular cAMP concentration was
measured using the cAMP Biotrak Enzymeimmunoassay (EIA)
system (#RPN2251, Amersham Biosciences Corp, Piscataway,
NJ) following the manufacturer’s instructions. The relative amount
of the intracellular cAMP (fmol) from VILIP-1 transgenic
keratinocytes was normalized with respect to the values obtained
from wild type keratinocyte cultures.
Mouse TIMP-1 assay
About 10 million mouse keratinocytes per 10-cm culture dish
were seeded. After 2 days in culture, the cells were washed twice
with PBS (calcium and magnesium free) and maintained in 10 ml
conditioned medium containing 1 part of KBM Basal Medium
(#CC-3101) and 2 parts of KBM Basal Medium without calcium
(#CC-3104) (Lonza, Walkersville, MD) for 1 day. The volume of
the conditioned medium was reduced to 150 ml by using Amicon
Ultra centrifugal filters (10k, #UFC901024) and Microcon YM-10
(#42407) (Millipore, Billerica, MA). The concentration of TIMP-1
in conditioned medium was measured using RayBio mouse
TIMP-1 ELISA kit (#ELM-TIMP1-001, RayBiotech Inc.,
Norcross, GA). Relative concentration of TIMP-1 (pg/ml) in
conditioned medium from VILIP-1 transgenic keratinocytes was
normalized with respect to the values obtained in conditioned
medium from wild type keratinocyte cultures.
Mouse MMP-9 assay
MMP-9 activity was determined by gelatinase zymography. 5 ml
of conditioned medium was mixed with 5 ml of Novex Tris-
Glycine SDS Sample Buffer (2x, #LC2676, Invitrogen, Carlsbad,
CA) and loaded on Novex 10% Zymogram (Gelatin) Gel
(#EC6175Box). The samples were fractionated in 1x Novex
Tris-Glycine SDS Running Buffer (#LC2675) for 90 min at
120V. After electrophoresis, the gel was incubated in Zymogram
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Zymogram Developing Buffer (#LC2671) overnight. The gel was
finally stained with Colloidal Blue Staining Kit (#LC6025) to
visualize the areas of protease activity.
Tumor induction experiments
Two stage carcinogenesis protocol. A single 100-nmol
initiating dose of DMBA in 0.2 ml acetone was applied topically to
shaved dorsal skin of 6–8 week-old female mice. One week after
DMBA treatment, TPA (4 mg) in 0.2 ml of acetone or acetone
alone was applied twice weekly to the skin for the duration of the
experiment (30 weeks). Tumor incidence and multiplicity were
observed weekly starting at 8 weeks of TPA promotion. The
number of mice per group was as follows: 28 wild-type mice, 30
K5-VILIP-1. Carcinomas were recorded by gross observation as
infiltrating and/or ulcerating lesions and confirmed by histological
analysis (see below). Autopsies of carcinoma-bearing mice were
performed and metastasis in axial lymph nodes, lung, liver and
spleen were recorded. All tumors were analyzed histologically.
Squamous cell carcinomas (SCC) were classified according to
histopathological grade [33]. Most SCCs were endophytic
growths that invaded the dermis and subcutaneous tissue. The
differentiation patterns defining the histopathological grade were:
a) Grade I SCC: Very well-differentiated with most of the tumor
containing keratinizing cells and horny pearls, b) Grade II SCC:
Moderately differentiated tumors in which up to 50% of the tumor
mass is formed by keratinizing cells c) Grade III SCC or poorly
differentiated tumors: Containing less than 25% tumor mass
showing evidence of keratinization, and d) Grade IV SCCs: Very
poorly differentiated tumors or spindle cell carcinomas containing
very little or no histological evidence of keratinization. Papilloma
and carcinoma were photographed at a magnification of 2.56(NA
0.08) and 106(NA 0.45) respectively.
Complete carcinogenesis protocol. 18 wild-type and 16
K5-VILIP-1 female mice were treated with 0.15 mmole (B(a)P)
twice weekly for 35 weeks in disposable cages, processed and
evaluated as described above for two stage carcinogenesis.
Analysis of epidermal thickness and cell proliferation
following treatment with TPA
Groups of wild-type or K5-VILIP-1 transgenic mice (n=5) were
treated with two applications of TPA (5 nmol) or the acetone
vehicle and sacrificed 48 hours after the last treatment. Untreated
mice were also included as control. Paraffin sections were stained
with hematoxilin and eosin (H&E) and the skin thickness was
measured with a micrometer. Ten measurements per mouse were
done in the interfollicular epidermis every 150 micrometers. For
analysis of cell proliferation, mice treated as described above, were
injected intraperitoneally with BrdU (100 mg/g body weight,
Sigma-Aldrich) in PBS, 2 hours prior to sacrifice. Treated skin was
then fixed in formalin, embedded in paraffin, sectioned at 4 mm,
stained with H&E and anti-BrdU antibody (Roche) (dilution 1/
100), and then treated with biotinylated anti-mouse IgG and
HRP-conjugated ABC reagent (Vector Laboratories Inc., Burlin-
game, CA). Slides were mounted and observed with a Nikon
Optiphot with a Plan/Apo objective 20X, NA, 0.75, Nikon
eyepiece X10, final magnification 6200. Epidermal cell prolifer-
ation (presented as BrdU labeled cells/mm of basement mem-
brane) was determined as follows: Basement membrane (BM)
length was determined in skin sections and the corresponding
number of BrdU labeled cells of the respective interfollicular
epidermal sector was counted. BM length determinations were
done with the aid of the Image Pro-Plus imaging software (Media
Cybernetics, Silver Spring, MD). BM length was determined in
acetone and TPA treated epidermis (3-5 mice per group, minimal
BM length/mouse was 2 mm per section).
Immunohistochemistry
Immunohistochemical procedures were performed on formalin-
fixed and paraffin-embedded dorsal skin and skin tumors. All
paraffin sections were subjected to previously published immuno-
staining protocols [33]. The same anti VILIP-1 antibody used in
Western blot analysis was employed as primary antibody at 1/500
and 1/1000 dilutions. An avidin-biotin-peroxidase kit (Vectastain
Elite, Burlingame, CA) was then employed followed by the
chromagen 3939-diaminobenzidine to develop the immunostain.
Negative controls, not incubated with VILIP-1 antibody, were
incubated with pre-immune serum at the same concentrations as
the primary antibody. Ki67 (Vector Labs., Burlingame, CA, rabbit
polyclonal VP-K451, 1/6000 dilution with antigen retrieval) and
MMP-9 (R&D Systems, Minneapolis, MN; goat anti mouse MMP-
9, AF909) were detected in tumors by immunohistochemistry using
similar procedures. Ki67 labeling index was determined in the basal
layer of papillomas (n=22) or basaloid SCC cells (defined as
carcinoma cells in contact with stroma) (n=20) from the two stage
carcinogenesis experiment by counting at least 400 cells per tumor.
MMP-9 was evaluated in twenty SCCs from the two stage
carcinogenesis experiment using a semiquantitative scale (Negative:
no stain; positive 1: moderate stain, mostly focal in nature, less than
50% of the tumor cells; positive 2: intense stain, more than 50% of
the tumor cells). All sections were counterstained with hematoxylin.
Statistical Analysis
Statistical significance was determined by calculating P values. P
values corresponding to the curves of carcinoma development
were determined two-tail T tests.
Supporting Information
Figure S1 Differentiation patterns in TPA treated epidermis.
After 2 topical applications of TPA the epidermis shows increased
thickening in both WT and K5-VILIP-1 mice. K1 and loricrin
(LOR) are clearly overexpressed in K5-VILIP-1 epidermis with
respect to WT epidermis (panels A-B and G-H). K6 and K14 are
marginally increased or unchanged when compared with trans-
genic epidermis (panels C-D and E-F). Marker immunohisto-
chemistry and hematoxylin counterstain, X200.
Found at: doi:10.1371/journal.pone.0010196.s001 (3.45 MB
TIF)
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